| 2026-02-27 |
详情>>
内部人交易：
Liddy Anne M.股份减少185.00股
|
| 2026-01-29 |
详情>>
业绩披露：
2026年一季报每股收益0.80美元,归母净利润1.79亿美元,同比去年增长-10.9%
|
| 2026-01-29 |
财报披露：
美东时间 2026-01-29 盘后发布财报
|
| 2026-01-22 |
详情>>
股本变动：
变动后总股本22324.49万股
|
| 2025-12-23 |
股东大会：
将于2026-02-05召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of October 21, 2025 (as it may be amended or supplemented from time to time, the “merger agreement”), by and among the Company, Hopper Parent Inc., a Delaware corporation (“Parent”), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will be merged with and into the Company (the “merger”), with the Company surviving the merger as a wholly owned subsidiary of Parent (the “surviving corporation”). We refer to this proposal as the “merger agreement proposal.”
2.To consider and vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger, which proposal we refer to as the “advisory compensation proposal.”
3.To consider and vote on a proposal to approve any adjournment of the special meeting for the purpose of soliciting additional proxies if there are insufficient votes at the special meeting to adopt the merger agreement, which proposal we refer to as the “adjournment proposal.”
|
| 2025-11-18 |
详情>>
业绩披露：
2023年年报每股收益1.85美元,归母净利润4.56亿美元,同比去年增长-64.98%
|
| 2025-11-18 |
详情>>
业绩披露：
2025年年报每股收益2.50美元,归母净利润5.66亿美元,同比去年增长-28.35%
|
| 2025-10-21 |
复牌提示：
2025-10-21 08:38:23 停牌，复牌日期 2025-10-21 09:00:00
|
| 2025-07-31 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.67美元,归母净利润3.79亿美元,同比去年增长-38.04%
|
| 2025-05-02 |
详情>>
业绩披露：
2025年中报每股收益0.81美元,归母净利润1.84亿美元,同比去年增长-55.91%
|
| 2025-02-06 |
详情>>
业绩披露：
2025年一季报每股收益0.87美元,归母净利润2.01亿美元,同比去年增长-18.46%
|
| 2025-01-16 |
股东大会：
将于2025-02-26召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2025 (Proposal No. 3);
4.To act upon a stockholder proposal regarding simple majority vote, if properly presented (Proposal No. 4);
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2024-11-27 |
详情>>
业绩披露：
2022年年报每股收益5.18美元,归母净利润13.02亿美元,同比去年增长-30.43%
|
| 2024-11-27 |
详情>>
业绩披露：
2024年年报每股收益3.35美元,归母净利润7.89亿美元,同比去年增长73.14%
|
| 2024-07-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益2.58美元,归母净利润6.11亿美元,同比去年增长67.19%
|
| 2024-05-03 |
详情>>
业绩披露：
2024年中报每股收益1.76美元,归母净利润4.16亿美元,同比去年增长2.59%
|
| 2024-02-02 |
详情>>
业绩披露：
2024年一季报每股收益1.03美元,归母净利润2.46亿美元,同比去年增长31.54%
|
| 2024-01-18 |
股东大会：
将于2024-03-07召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the nine (9) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year;
2.To conduct an advisory vote to approve our executive compensation;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2024
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2023-01-19 |
股东大会：
将于2023-03-09召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the nine (9) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To conduct an advisory vote on the frequency of future advisory votes to approve our executive compensation (Proposal No. 3);
4.To approve the Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan (Proposal No. 4);
5.To approve the Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan (“ESPP”) (Proposal No. 5);
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2023 (Proposal No. 6);
7.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2023-01-19 |
股东大会：
将于2023-03-09召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the nine (9) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To conduct an advisory vote on the frequency of future advisory votes to approve our executive compensation (Proposal No. 3);
4.To approve the Hologic, Inc. Amended and Restated 2008 Equity Incentive Plan (Proposal No. 4);
5.To approve the Hologic, Inc. Amended and Restated 2012 Employee Stock Purchase Plan (“ESPP”) (Proposal No. 5);
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2023 (Proposal No. 6);
7.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2022-01-20 |
股东大会：
将于2022-03-10召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight (8) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year
2.To conduct an advisory vote to approve our executive compensation
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2022
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-21 |
股东大会：
将于2021-03-11召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight (8) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2021 (Proposal No. 3);
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2020-01-22 |
股东大会：
将于2020-03-05召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight (8) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2020 (Proposal No. 3);
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-01-18 |
股东大会：
将于2019-03-07召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight (8) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year (Proposal No. 1);
2.To conduct an advisory vote to approve our executive compensation (Proposal No. 2);
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2019 (Proposal No. 3);
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-01-26 |
股东大会：
将于2018-03-14召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the seven (7) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year;
2.To conduct an advisory vote to approve our executive compensation;
3.To approve the amended and restated Hologic, Inc. 2008 Equity Incentive Plan;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2018 (Proposal No. 4);
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-01-20 |
股东大会：
将于2017-03-08召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the eight (8) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year;
2.To conduct an advisory vote to approve our executive compensation;
3.To conduct an advisory vote on the frequency of future advisory votes to approve our executive compensation;
4.To approve an amendment to the Company’s Bylaws to implement majority voting in uncontested director elections;
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2017;
6.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-01-20 |
股东大会：
将于2016-03-02召开股东大会
会议内容 ▼▲
- 1.To consider and act upon the election of the ten (10) nominees identified in the accompanying proxy statement to serve as directors for the ensuing year;
2.To vote on a non-binding advisory resolution to approve executive compensation;
3.To approve an amendment to the Hologic, Inc. 2012 Employee Stock Purchase Plan (“ESPP”), as described in this proxy statement;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2016;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|